3Helix is a platform collagen company developing diagnostics for fibrotic conditions and advancing tissue regeneration science. The company's proprietary technology, Collagen Hybridizing Peptides (CHPs), was developed by Michael Yu, a current faculty member at University of Utah. CHPs enable the targeting of remodeling/damaged collagen.
The team is currently focused on commercializing fibrotic diagnostics. CHPs allow clinicians to determine the progression of the fibrosis by monitoring the collagen turnover. One exciting use case Is a histopathology approach to stratify NASH patients to reduce unnecessary therapeutic intervention. Additional noninvasive approaches can be achieved using the CHP platform such as medical Imaging and serum testing.
Notably, Mike Kirkness, CEO, has secured a material collaboration with Roche's ophthalmology division to develop a noninvasive diagnostic for subretinal fibrosisin nAMD.
CEO
CTO
Co-Founder
Stay connected to everything happening at Altitude Lab.
You can trust us with your email. We don't spam.